Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674

Active Not RecruitingNA

Sponsor: Medtronic Vascular

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus

Interventions: Renal Denervation (Symplicity Spyral™)

Countries: United States, Australia, Belgium, France, Germany, Greece, Ireland, Monaco

The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg
2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg
3. Individual has an average systolic baseline home blood pressure ≥135 mmHg

Exclusion Criteria:

1. Individual lacks appropriate renal artery anatomy
2. Individual has undergone prior renal denervation
3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement
4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
5. Individual has an estimated glomerular filtration rate (eGFR) of \<45
6. Individual has one or more episode(s) of orthostatic hypotension
7. Individual is pregnant, nursing or planning to become pregnant
8. Individual has primary pulmonary hypertension
9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%
Locations (99)
  • Birmingham, Alabama, United States
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Little Rock, Arkansas, United States
  • La Jolla, California, United States
  • San Francisco, California, United States
  • Stanford, California, United States
  • Aurora, Colorado, United States
  • Lakewood, Colorado, United States
  • Hartford, Connecticut, United States
  • Washington D.C., District of Columbia, United States
  • Clearwater, Florida, United States
  • Clearwater, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Orlando, Florida, United States
  • Safety Harbor, Florida, United States
  • Tallahassee, Florida, United States
  • Atlanta, Georgia, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Maywood, Illinois, United States
  • Palos Park, Illinois, United States
  • Indianapolis, Indiana, United States
  • West Des Moines, Iowa, United States
  • Baltimore, Maryland, United States
  • Towson, Maryland, United States
  • + 69 more on CT.gov